2020 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

February 2020 | 51 pages | ID: 28E488BE5609EN
VPAResearch

Abstracts

The 2020 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline report presents a comprehensive overview of the research and development of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Pre-clinical phase, three drugs in Phase 1, two drugs in Phase 2 and two drugs in Phase 3

As of February 2020, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline remains robust with 9 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment. Diverse types of targeted therapies are being explored through clinical trials including Fc receptor antagonists; Immunomodulators; Immunostimulators; Lectin/Protein Modulators; Neonatal Fc receptor antagonists; Toll-like receptor 4 antagonists.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

PUBLISHER EXPERTISE

VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

SCOPE:

• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) development
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline candidates included
• Business overview and snapshot of all companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline are included
• Latest market and pipeline developments are provided in the report

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline companies included in the report are- Argenx SE, GeNeuro SA, Immupharma Plc, MedDay Pharmaceuticals, Momenta Pharmaceuticals Inc, Octapharma AG, Pfizer Inc, Takeda Pharmaceutical Co Ltd, UCB SA

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline drugs profiled in the report include- efgartigimod alfa, GNbAC1 (temelimab), P140 (forigerimod), M254, Immune Globulin Human, PF-06755347 (GL-2045), HYQVIA, rozanolixizumab, MD1003

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. EXECUTIVE SUMMARY

2.1 Report Scope and Research Methodology
2.2 Introduction to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Condition
2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Snapshot, 2020
2.4 Companies investing in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline therapeutics
2.5 Phase wise Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Products
2.7 Route of Administration of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Drugs

3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT

3.1 Argenx SE Overview, Contacts and ASD Pipeline Drugs
3.2 GeNeuro SA Overview, Contacts and ASD Pipeline Drugs
3.3 Immupharma Plc Overview, Contacts and ASD Pipeline Drugs
3.4 MedDay Pharmaceuticals Overview, Contacts and ASD Pipeline Drugs
3.5 Momenta Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Octapharma AG Overview, Contacts and ASD Pipeline Drugs
3.7 Pfizer Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Takeda Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.9 UCB SA Overview, Contacts and ASD Pipeline Drugs

4. ACTIVE PIPELINE DRUG DETAILS, 2020

4.1 efgartigimod alfa Drug Details
  4.1.1 efgartigimod alfa Current Status
  4.1.2 efgartigimod alfa Drug Overview
  4.1.3 efgartigimod alfa Mechanism of Action
  4.1.4 efgartigimod alfa Licensing/Collaboration Companies
  4.1.5 efgartigimod alfa Clinical Trials
4.2 GNbAC1 (temelimab) Drug Details
  4.2.1 GNbAC1 (temelimab) Current Status
  4.2.2 GNbAC1 (temelimab) Drug Overview
  4.2.3 GNbAC1 (temelimab) Mechanism of Action
  4.2.4 GNbAC1 (temelimab) Licensing/Collaboration Companies
  4.2.5 GNbAC1 (temelimab) Clinical Trials
4.3 P140 (forigerimod) Drug Details
  4.3.1 P140 (forigerimod) Current Status
  4.3.2 P140 (forigerimod) Drug Overview
  4.3.3 P140 (forigerimod) Mechanism of Action
  4.3.4 P140 (forigerimod) Licensing/Collaboration Companies
  4.3.5 P140 (forigerimod) Clinical Trials
4.4 M254 Drug Details
  4.4.1 M254 Current Status
  4.4.2 M254 Drug Overview
  4.4.3 M254 Mechanism of Action
  4.4.4 M254 Licensing/Collaboration Companies
  4.4.5 M254 Clinical Trials
4.5 Immune Globulin Human Drug Details
  4.5.1 Immune Globulin Human Current Status
  4.5.2 Immune Globulin Human Drug Overview
  4.5.3 Immune Globulin Human Mechanism of Action
  4.5.4 Immune Globulin Human Licensing/Collaboration Companies
  4.5.5 Immune Globulin Human Clinical Trials
4.6 PF-06755347 (GL-2045) Drug Details
  4.6.1 PF-06755347 (GL-2045) Current Status
  4.6.2 PF-06755347 (GL-2045) Drug Overview
  4.6.3 PF-06755347 (GL-2045) Mechanism of Action
  4.6.4 PF-06755347 (GL-2045) Licensing/Collaboration Companies
  4.6.5 PF-06755347 (GL-2045) Clinical Trials
4.7 HYQVIA Drug Details
  4.7.1 HYQVIA Current Status
  4.7.2 HYQVIA Drug Overview
  4.7.3 HYQVIA Mechanism of Action
  4.7.4 HYQVIA Licensing/Collaboration Companies
  4.7.5 HYQVIA Clinical Trials
4.8 rozanolixizumab Drug Details
  4.8.1 rozanolixizumab Current Status
  4.8.2 rozanolixizumab Drug Overview
  4.8.3 rozanolixizumab Mechanism of Action
  4.8.4 rozanolixizumab Licensing/Collaboration Companies
  4.8.5 rozanolixizumab Clinical Trials
4.9 MD1003 Drug Details
  4.9.1 MD1003 Current Status
  4.9.2 MD1003 Drug Overview
  4.9.3 MD1003 Mechanism of Action
  4.9.4 MD1003 Licensing/Collaboration Companies
  4.9.5 MD1003 Clinical Trials

5. LATEST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE NEWS AND DEALS

6. APPENDIX

6.1 Our Databases and Reports
6.2 Research Methodolgy